By Fineline Cube GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application (MAA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB) in adults. If approved, bepirovirsen would become the first therapy to combine three distinct mechanisms—viral replication inhibition, HBsAg reduction, and immune reactivation—in a single agent, potentially enabling a functional cure for a disease affecting over 250 million people globally.
Regulatory Milestone
| Event | Status |
|---|---|
| MAA Submission | Accepted by EMA (validated for review) |
| Indication | Chronic hepatitis B in adults |
| Therapeutic Class | Antisense oligonucleotide (ASO) |
| Next Steps | Standard EMA review timeline (~12–18 months); potential approval in 2027 |
This marks a critical step toward making bepirovirsen the first disease-modifying therapy for CHB beyond lifelong nucleos(t)ide analogs.
Triple Mechanism of Action
Bepirovirsen is designed to bind hepatitis B virus (HBV) mRNA and pregenomic RNA, triggering their degradation via RNase H1. This leads to:
- Inhibition of viral genome replication – Reduces production of new virions
- Reduction of hepatitis B surface antigen (HBsAg) – Lowers levels of this key immune-tolerance driver
- Immune system reactivation – Restores T-cell and B-cell responses, increasing chances of durable functional cure (defined as sustained HBsAg loss with or without anti-HBs seroconversion)
Unlike current therapies that suppress replication but rarely achieve HBsAg loss (<1–3% annually), bepirovirsen targets the root cause of viral persistence.
Clinical Context & Unmet Need
- Current Standard: Lifelong nucleos(t)ide analogs (e.g., entecavir, tenofovir) suppress HBV DNA but do not eliminate cccDNA or significantly reduce HBsAg
- Functional Cure Rate: <10% with existing regimens; most patients remain at risk of cirrhosis and hepatocellular carcinoma
- Market Opportunity: First therapy to offer finite-duration treatment with curative potential could capture significant share in a $5B+ global CHB market
Phase II data showed ~10% of patients achieved functional cure after 24 weeks of bepirovirsen—rates unprecedented for a monotherapy.
Strategic Significance for GSK
- Hepatology Revival: Re-establishes GSK as a leader in liver disease after exiting earlier programs
- Platform Validation: Success would validate ASOs as viable modality in infectious disease—not just rare genetic disorders
- Combination Potential: Future trials may pair bepirovirsen with therapeutic vaccines or checkpoint inhibitors to boost cure rates beyond 20%
The MAA acceptance follows positive feedback from the FDA, which granted Breakthrough Therapy Designation in 2025.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approval, clinical efficacy, and commercial potential. Actual outcomes may differ due to EMA assessment, safety findings, and competitive developments.-Fineline Info & Tech